Figure 1. Consolidated Standards of Reporting Trials Diagram.

Assignment to the 4 treatment groups, numbers of drop-in/drop-out, and numbers included in intention-to-treat (ITT) and per-protocol analyses. For the ITT analyses, 98 participants in the glargine (n = 36), glimepiride (n = 22), liraglutide (n = 28), and sitagliptin (n = 12) groups were removed from the randomized group (n = 5047) due to not having at least 1 follow-up estimated glomerular filtration rate or 1 follow-up urinary albumin-to-creatinine ratio measure obtained after the baseline visit. For the per-protocol analyses, 247 participants in the glargine (n = 61), glimepiride (n = 44), liraglutide (n = 112), and sitagliptin (n = 30) groups were removed from the randomized group (n = 5047) if they did not attend any follow-up visits or did not take at least 1 dose of their randomized medication. GLP-1 RA indicates glucagonlike peptide-1 receptor agonist; SGLT2, sodium-glucose cotransporter-2.